Comparative Antianaerobic Activities of Doripenem Determined by MIC and Time-Kill Analysis

@article{Credito2007ComparativeAA,
  title={Comparative Antianaerobic Activities of Doripenem Determined by MIC and Time-Kill Analysis},
  author={K. Credito and L. Ednie and P. Appelbaum},
  journal={Antimicrobial Agents and Chemotherapy},
  year={2007},
  volume={52},
  pages={365 - 373}
}
ABSTRACT Against 447 anaerobe strains, the investigational carbapenem doripenem had an MIC50 of 0.125 μg/ml and an MIC90 of 1 μg/ml. Results were similar to those for imipenem, meropenem, and ertapenem. Time-kill studies showed that doripenem had very good bactericidal activity compared to other carbapenems, with 99.9% killing of 11 strains at 2× MIC after 48 h. 
[Doripenem: need for a new carbapenem].
  • B. Guery
  • Medicine
  • Medecine et maladies infectieuses
  • 2009
TLDR
Doripenem was evaluated in nosocomial pneumonia including ventilator-acquired pneumonia, complicated intra-abdominal infection, and complicated urinary tract infection and showed an interesting activity in P. aeruginosa infected patients. Expand
Activity of a novel carbapenem, doripenem, against anaerobic pathogens.
TLDR
Doripenem has been shown to be active in vitro against strains isolated from a variety of clinical infections and in intra-abdominal and pelvic sites and seems comparable with the other extant carbapenems. Expand
Antianaerobic Activity of Sulopenem Compared to Six Other Agents
ABSTRACT Agar dilution MIC methodology was used to compare the activity of sulopenem with those of amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin-tazobactam, imipenem, clindamycin, andExpand
In Vitro and In Vivo Activities of the Novel Ketolide RBx 14255 against Clostridium difficile
TLDR
In the hamster model of C. difficile infection, RBx 14255 demonstrated greater efficacy than metronidazole and vancomycin, making it a promising candidate for C. Difficile treatment. Expand
A Review of Doripenem for the Treatment of Serious Bacterial Infections
TLDR
Doripenem may represent a valuable option when carbapenem therapy is warranted for the treatment of serious infection, particularly in cases in which the etiology is a drug-resistant, Gram-negative pathogen. Expand
[Role of new carbapenems in nosocomial intraabdominal infection].
  • J. Aguado
  • Medicine
  • Enfermedades infecciosas y microbiologia clinica
  • 2010
TLDR
Doripenem is a valuable addition to the options available for the empirical treatment of hospitalized patients with serious intraabdominal infections and was more effective in the treatment of patients with Pseudomonas aeruginosa. Expand
Characteristics of doripenem: a new broad-spectrum antibiotic
TLDR
Doripenem is a new parenteral antibiotic from the carbapenem class that has a broad-spectrum activity against Gram-positive, Gram- negative, and anaerobic bacteria and may be used for empirical treatment of multibacterial infections produced by potentially multiresistant Gram-negative bacilli. Expand
Comparative review of imipenem/cilastatin versus meropenem.
TLDR
Meropenem is preferred for daily use in healthcare services when carbapenems are to be used, and its stability and its milder adverse effects distinguish it from imipenem-cilastatin. Expand
DDDT-3083-Characteristics of doripenem: a new broad-spectrum
Correspondence: Francisco Alvarez-Lerma intensive Care Unit, Hospital del Mar, Passeig Marítim, 25-29, 08003, Barcelona, Spain Tel +34 93 248 3125 Fax +34 93 248 3254 email falvarez@imas.imim.esExpand
Doripenem: The Newest Addition to Carbapenem Antibiotics
TLDR
Doripenem has been shown to be an effective and well-tolerated carbapenem antibiotic for the treatment of complicated urinary tract infections and complicated intraabdominal infections and has exhibited promising results in studies evaluating its use in patients with nosocomial pneumonia. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 19 REFERENCES
Activities of Doripenem (S-4661) against Drug-Resistant Clinical Pathogens
TLDR
Doripenem was the most active carbapenem (MIC90, 1 to 4 μg/ml) against penicillin-resistant streptococci and was the best candidate for treating endemic extended-spectrum β-lactamase- and stably derepressed AmpC-producing enteric bacilli. Expand
In Vitro Activities of Doripenem and Comparator Agents against 364 Anaerobic Clinical Isolates
TLDR
Doripenem appears to have excellent activity against a broad range of anaerobes and was either comparable to or slightly less active than imipenems and meropenem against most isolates but more active than the other penems against Clostridium difficile. Expand
In Vitro Antimicrobial Activity of Doripenem, a New Carbapenem
TLDR
Overall, doripenem demonstrated in vitro activity similar to that of meropenem against gram-negative pathogens and to that that of imipenen against Gram-positive pathogens. Expand
In Vitro Antianaerobic Activity of Ertapenem (MK-0826) Compared to Seven Other Compounds
TLDR
Time-kill studies revealed that ertapenem at two times the MIC was bactericidal for 9 of 10 strains after 48 h, and the kinetics for other β-lactams were similar to those of ertAPenem. Expand
In Vitro Activity of Doripenem (S-4661) against Multidrug-Resistant Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis
TLDR
Doripenem had somewhat better activity than established antimicrobial agents and was well tolerated by patients with cystic fibrosis. Expand
Time-Kill Studies of the Antianaerobe Activity of Garenoxacin Compared with Those of Nine Other Agents
TLDR
At two times the MIC, garenoxacin was bactericidal against 19 of 20 strains after 48 h and against 17 of 20 after 24 h and other drugs, except clindamycin, gave killing rates similar to those for garenxacin. Expand
Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
  • T. Fritsche, M. Stilwell, R. Jones
  • Biology, Medicine
  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2005
TLDR
Doripenem displays the favourable characteristics of other carbapenems, and appears to offer certain advantages in terms of potency, spectrum and beta-lactamase stability when compared with some carbAPenems used currently to treat nosocomial infections. Expand
Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology
TLDR
All compounds were bactericidal at the MIC after 48 h; after 24 h, 90% killing was shown for all strains when the compounds were used at four times the MIC. Expand
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
TLDR
Doripenem appears to be a potent carbapenem with a spectrum resembling currently marketed antipseudomonalcarbapenems, but with greater activity when tested against some non-fermentative bacillary strains. Expand
Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium.
TLDR
There is a need for new agents for the treatment of infections caused by vancomycin- and gentamicin-resistant Enterococcus faecium (VGREF) that may be resistant to all available antimicrobial agents, and the activity of quinupristin/dalfopristin may be enhanced against some strains by reversing the concentrations of its two components, quin upristin and dalfoprisin, as that may occur in vivo. Expand
...
1
2
...